Overview

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Status:
Not yet recruiting
Trial end date:
2021-07-23
Target enrollment:
Participant gender:
Summary
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Collaborator:
Eisai Inc.
Treatments:
Lenvatinib